Findings
========

Introduction
------------

*Acinetobacter baumannii* (*A. baumannii )* was identified from the environment in the early twentieth century, and has been isolated worldwide. The rapid spread of multidrug-resistant *A. baumannii* (MDRAB) in clinical settings has made choosing an appropriate antibiotic to treat these infections difficult for clinicians. *A. baumannii* within genetically uniform populations exhibit significant phenotypic variability \[[@B1]\]. For example, antibiotic susceptible clinical *A. baumannii* isolates can develop antibiotic resistant phenotypes, in a process called phenotype switching. Such phenotype switching can be perplexing for clinicians, in both interpreting microbiological results and choosing effective antibiotics.

Shanley *et al*. showed that *Acinetobacter calcoaceticus* can naturally uptake, incorporate, and stably maintain DNA *in vitro*\[[@B2]\]. Only a few reports have mentioned the rapid adaptation of *A. baumannii* isolates in a hospital environment \[[@B3],[@B4]\]. Determining whether the multiple resistance phenotype switching is due to cross-infection from neighboring patients or from natural mutation of the same *A. baumannii* isolate is important because of the different strategies needed to resolve the clinical issues. Here we report the rapid change of resistance phenotype of clinical *A. baumannii* isolates from individual patients during the same admission at a single medical institution in Taiwan.

Material and methods
--------------------

### Isolates and phenotyping

We designed a chronological study to collect pairs of phenotypically-identified *A. baumannii* isolates from individual patients during the same hospitalization period at Changhua Christian Hospital (CCH). Pool of samples for further analysis was collected from January 1 1998 to December 31 2008. Among those samples, there were three pairs of clinical *A. baumannii* isolates from CCH that met the inclusion criteria: Pair 1 (isolates 29-4 and 29-43, numbered according to their position in the CCH Bacterial Bank), Pair 2 (isolates 10-18 and 10-10), and Pair 3 (isolates 14-91 and 14-81). Phynotypic method to identify those *A. baumannii* isolates is using a Vitek-2 System (BioMerieux, Marcy l\'Etoile, France). And, the isolates were identified according to 16S ribosomal RNA region at the molecular level, as previously described \[[@B5]\].

### DNA isolation, ribotyping, and detection of short tandem repeats (STR) from clinical *A. baumannii* isolates

Genomic DNA was isolated from three colonies from an overnight culture grown on blood agar plates (bioMérieux, Den Bosch, The Netherlands) using a Bacterial Genomic DNA Isolation Kit III according to the manufacturer's instructions (Roche, Mannheim, Germany). The ribotype pattern was interpreted to identify the group to which each strain belonged, as previously described \[[@B6]\]. The primer pair *REP1R-I* (5-IIIICGICGICATCIGGC-3) and *REP2-I* (5-ICGICTTATCIGGCCTAC-3) \[[@B7]\] was used to amplify putative *REP*-like elements from the bacterial DNA.

### Pulsed field gel electrophoresis

We followed a standard protocol for pulsed-field gel electrophoresis (PFGE) analysis of the *A. baumannii* isolates. In brief, *A. baumannii* were plated on blood agar and incubated in a 5% CO~2~ atmosphere at 35°C for 16--24 h. Plug slices were digested with 20 U of *Sgr*AI. The DNA fragments were then separated in 1% Seakem Gold agarose gels (FMC BioProducts) at 14°C using a Bio-Rad CHEF DRIII PFGE system (Bio-Rad Laboratories, Hercules, CA, USA). Gels were run in 0.5× Tris-borate-EDTA (TBE; pH 8) at a 120° fixed angle and a fixed voltage (6 V/cm), with pulse intervals from 4--40 s for 20 h. Following staining and imaging, the chromosomal DNA restriction patterns produced by PFGE were interpreted using Tenover's categorization \[[@B8]\].

### Multilocus sequence typing

Multilocus sequence typing (MLST) was performed according to the method of Bartual *et al*. \[[@B9]\]. In brief, housekeeping genes for MLST were selected based on their sequence availability in GenBank, on prior studies of the phylogenetic relationships for the genus *Acinetobacter*, and on their use in MLST schemes for other bacterial species \[[@B1],[@B10]-[@B12]\]. PCR primers were chosen from previous studies or were newly designed for amplification of the seven selected genes: citrate synthase (*gltA*), DNA gyrase subunit B (*gyrB*), glucose dehydrogenase B (*gdhB*), homologous recombination factor (*recA*), 60 kDa chaperonin (*cpn60*), glucose-6-phosphate isomerase (*gpi*), RNA polymerase 70 factor (*rpoD*). All PCR amplifications were performed in a MasterCycler gradient instrument (Eppendorf, Hamburg, Germany). Sequencing of internal fragments (\~450 bp in size) of the selected housekeeping genes was performed in an ABI Prism 377 sequencer using the ABI Prism BigDye terminator cycle sequencing ready reaction kit v. 2 (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's recommendations.

Results
-------

We collected clinical and microbiological profiles focusing on the three pairs of *A. baumannii* isolates from patients during an individual hospitalization. All three patients stayed at our institute for at least two weeks, and all of them received antibiotics following identification of the *A. baumannii* isolates (Table [1](#T1){ref-type="table"}). The antibiotic susceptibility of clinical *A. baumannii* isolates are listed in Table [2](#T2){ref-type="table"}. Four PFGE fingerprint patterns were detected in the three pairs of *A. baumannii* isolates in Figure [1](#F1){ref-type="fig"}. Furthermore, there appears to be a clear link of cross-infection between the PFGE types and the clinical data available for the isolates. Interpretation of the MLST data revealed that more than half of the MLST allelic profiles from the three pairs of *A. baumannii* isolates differed from those already in *A. baumannii* MLST databases (<http://pubmlst.org/abaumannii/)>\[[@B13]\]. Comparison of the sequence types (ST) of the three paired *A. baumannii* isolates showed similarity between the 29-4 and 29-43 *A. baumannii* isolates, especially in the allelic profiles of *gltA, gdhB, recA,* and *rpoD* (Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}). However, there was a difference between the 14-91 and 14-81 paired isolates, especially in the allelic profiles of *recA, cpn60*, and *rpoD* (Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}). These results indicated that isolates 29-4 and 29-43 are the same isolate, and that both paired 14-91 and 14-81 isolates and paired 10-18 and 10-10 isoaltes are different isolates (Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}). The fingerprint patterns of the STRs were quite varied (Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}). It is particularly interesting that rapid phenotype switching between the paired isolates (29-4 and 29-43) could occur during one course of antibiotic treatment.

###### 

The time line of antimicrobial agents prescription

  **Event**             **Date**            **Patient number one, Pair 1**   **Date**              **Patient number two, Pair 2**               **Date**              **Patient number three, Pair 3**
  --------------------- ------------------- -------------------------------- --------------------- -------------------------------------------- --------------------- ----------------------------------
  Admission day         July 29             Admission day                    July 2                Admission day                                June 3                Admission day
  Antimicrobial agent   July 29 and Aug 4   Cefuroxime                       July 2 and July 19    Ampicillin-sulbactam                         June 3 and June 10    Ampicillin-sulbactam
  Isolation day         Aug 2               Isolates 10-10 from sputum       July 19               Isolates 29-43 from sputum                   June 7                Isolates 14-91 from sputum
  Antimicrobial agent   Aug 4 and Aug 7     Ceftazidime                      July 19 and July 26   Piperacillin-tazobactam                      June 10 and June 17   Cefotaxime
  Antimicrobial agent   Aug 7 and Aug 10    Piperacillin-tazobactam          July 26 and Aug 1     Levofloxacin                                 June 17 and June 24   Piperacillin-tazobactam
  Antimicrobial agent   Since Aug 10        Imipenem-cilastatin              Since Aug 1           Imipenem-cilastatin                          Since June 24         Meropenem
  Isolation day         Aug 16              Isolates 10-10 from abscess      Aug 18                Isolates 29-4 from tip of central catheter   July 7                Isolates 14-81 from sputum

###### 

**Antibiotic susceptibility of clinical*Acinetobacter baumannii*isolates**

  **Number of isolate**   **10-10**                             **10-18**               **29-43**                             **29-4**                     **14-91**                             **14-81**
  ----------------------- ------------------------------------- ----------------------- ------------------------------------- ---------------------------- ------------------------------------- -------------------------------------
  Date of isolation       2-Aug                                 16-Aug                  19-Jul                                18-Aug                       9-Jun                                 7-Jul
  Time of isolation       PM 02:38:55                           PM 03:10:10             PM 04:21:03                           PM 02:47:06                  AM 09:12:47                           AM 10:18:53
  Diagnosis               pneumonia                             Soft tissue infection   pneumonia                             Catheter-related infection   pneumonia                             pneumonia
  Specimens               Sputum, tracheal aspirate (suction)   abscess                 Sputum, tracheal aspirate (suction)   Tip of central catheter      Sputum, tracheal aspirate (suction)   Sputum, tracheal aspirate (suction)
  Antibiotic              Minimum inhibitory                    concentrations          (ug/mL)                                                                                                   
  AN                      8                                     128                     8                                     128                          8                                     64
  SAM                     32                                    128                     32                                    128                          32                                    128
  CTZ                     8                                     64                      8                                     64                           8                                     32
  LVF                     2                                     128                     2                                     128                          2                                     64
  IMP                     2                                     16                      2                                     16                           2                                     16
  PIP-TAZ                 8                                     256                     8                                     256                          8                                     256
  CRO                     8                                     128                     8                                     128                          8                                     64
  CFP                     8                                     256                     8                                     256                          8                                     128
  MEP                     4                                     32                      4                                     32                           4                                     16

Notes: The susceptibility tests were performed using the Vitek-2 GN card (Biomerieux, Marcy l\'Etoile, France). The results were interpreted using the CLSI breakpoints (Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility testing; Twenty-First Information Supplement. CLSI document M100-S21, CLSI, Wayne, PA; 2011).

AN: amikacin; SAM: ampicillin-sulbactam; CTZ: ceftazidime; LVF: levofloxacin; IMP: imipenem-cilastatin; PIP-TAZ: piperacillin-tazobactam; CRO: ceftriaxone; CFP:cefepime; MEP: meropenem; colistin and tigecycline and polymyxin B were not provided by Vitek-2 System.

![**PFGE fingerprints of three pairs of clinical*A. baumannii*isolates following digestion with the*Sgr*AI restriction enzyme.**](1476-0711-12-21-1){#F1}

###### 

**The results of pulsed field gel electrophoresis, multilocus sequence typing, and short tandem repeat analysis of three pairs of*A. baumannii*isolates**

  **Isolates**   **Geno type(†)**   **PFGE type**   **ST Type(‡)**    ***gltA***   ***gyrB***   ***gdhB***   ***recA***   ***cpn60***   ***gpi***    ***rpoD***   **STR type**
  -------------- ------------------ --------------- ----------------- ------------ ------------ ------------ ------------ ------------- ------------ ------------ --------------
  10-18          Ab 1               A               this study (a1)   6            this study   this study   this study   this study    this study   this study   I
  10-10          Ab 2               A               this study (a2)   11           this study   this study   this study   this study    this study   this study   II
  29-4           Ab 3               B               this study (a3)   1            this study   3            2            2             this study   3            III
  29-43          Ab 3               B               this study (a4)   1            3            3            2            this study    7            3            IX
  14-91          Ab 4               C               this study (a5)   1            this study   this study   2            1             23           18           X
  14-81          Ab 5               D               this study (a6)   1            this study   3            2            2             this study   3            XI

Notes

Sequences of amplified genes were compared with sequences from the *A. baumannii* MLST website (<http://pubmlst.org/abaumannii/>).

ST: sequence type.

† the given name of the genotype is defined as *A. baumannii +* number (Ab + number).

‡ the given name of the genotype is defined as *Acinetobacter* isolate + number (a + number).

###### 

**Aligmnent for three pairs of*Acinetobacter baumannii*siolates**

  **10-10 VS 10-18**   **gltA**   **gyrB**   **gdhB**   **recA**   **cpn60**   **gpi**   **rpoD**
  -------------------- ---------- ---------- ---------- ---------- ----------- --------- ----------
  Length               484        927        744        371        454         358       860
  Score                684        1218       1258       667        819         662       1589
  Identities           446/484    835/922    699/707    361/361    446/447     358/358   860/860
  Difference           38         87         8          0          1           0         0
  Gaps                 0/484      4/922      4/707      0/361      1/447       0/358     0/860
  29-4 VS 29-43        gltA       gyrB       gdhB       recA       cpn60       gpi       rpoD
  Length               484        936        396        371        454         363       513
  Score                894        806        732        686        778         464       948
  Identities           484/484    450/457    396/396    371/371    421/421     265/272   513/513
  Difference           0          7          0          0          0           7         0
  Gaps                 0          0          0          0          0           0         0
  14-91 VS 14-81       gltA       gyrB       gdhB       recA       cpn60       gpi       rpoD
  Length               484        932        396        371        421         360       513
  Score                894        1701       399        686        773         392       931
  Identities           484/484    924/925    318/369    371/371    420/421     253/273   510/513
  Difference           0          1          51         0          1           20        3
  Gaps                 0          1          0          0          0           2         0

Discussion
----------

The is the first report of phenotype switching of antibiotic resistance in clinical *A. baumannii* isolates in individual patients during the same hospitalization in Taiwan. While *A. baumannii* has been reported previously in Taiwan, and prolonged administration of broad-spectrum antibiotics will induce the development of antibiotic resistance in clinical *A. baumannii* isolates, little is known about the current clinical situation. It was demonstrated that a important evolutionary change of a single genotype was fundamental to the continuous rise observed in the number of *A. baumannii* infections \[[@B4]\].

The current study suggests that natural transformation and mutation of genotypes occurred in clinical *A. baumannii* isolates 29-43 and 29-4 on the basis of PFGE. We used three methods to determine the genetic similarity of the paired *A. baumannii* isolates: PFGE, MLST, and STR. Snelling *et al*. described a PCR assay using repetitive extragenic palindromic sequences to type *A. calcoaceticus* and *A. baumannii* strains \[[@B14]\], while Alcala *et al*. characterized a meningococcal epidemic wave using a MLST method \[[@B15]\], similar to that used in our study. The congruence between the MLST, PFGE, and STR data suggests that the findings of the current study are sound; however, further experiments are required to prove the relationships among the paired isolates.

In this study, we discovered natural mutation and rapid change of antibiotic resistance phenotype of clinical *A. baumannii* isolates from an individual patient. This is alarming as this particular clone seems to be able to effectively fill niches that were essentially uninhabited by *A. baumannii* in the past. Even in a relatively closed environment, the isolates of identical PFGE fingerprint patterns showed a variety of MLST patterns. Apparently, the MLST patterns of paired isolates 29-4 and 29-43 are capable of withstanding background mutation. It is possible that the mutation rate of this particular isolate may contribute to its success in coping with different environments.

Conclusions
-----------

This study provides novel insight into the clinical problem of whether different *A. baumannii* isolates from the same patient are due to cross-infection from neighboring patients or from natural mutation. This is important for clinicians because the treatments for the two causes are different. The approach for the first phenomenon is to enhance contact precautions in the clinical practice, whereas the second is the stepwise prescription of different antibiotics.
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